During the past decade, NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Affiris AG" with 2 trials sponsored, "Celgene" with 2 trials sponsored, "MedDay Pharmaceuticals SA" with 1 trials sponsored and "Medical Valley Digital Health Application Center GmbH" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH" #1 collaborator was "Fraunhofer Institute for Integrated Circuits IIS" with 1 trials as a collaborator, "Friedrich-Alexander-Universität Erlangen-Nürnberg" with 1 trials as a collaborator, "Hospital Rummelsberg" with 1 trials as a collaborator, "Leibniz Centre for European Economic Research GmbH" with 1 trials as a collaborator and "NeuroPoint GmbH" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH" are "Multiple Sclerosis" (4 trials), "Alzheimer's Disease" (1 trials), "Alzheimer´s Disease" (1 trials), "Gait Disorders, Neurologic" (1 trials) and "Idiopathic Parkinson Disease" (1 trials). Many other conditions were trialed in "NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH" in a lesser frequency.

Most popular intervention types in "NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH" are "Drug" (6 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (3 trials), "AFFITOPE® AD02" (1 trials), "Interferon beta-1a" (1 trials), "MD1003 100mg capsule" (1 trials) and "Ozanimod" (1 trials). Other intervention names were less common.

The vast majority of trials in "NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH" are 10 trials for "All" genders.

Currently, there are NaN active trials in "NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".